<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High levels of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>), known as <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> (HHcy), are associated with cerebrovascular diseases, such as vascular <z:hpo ids='HP_0000726'>dementia</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, and <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The γ-amino <z:chebi fb="4" ids="30772">butyric acid</z:chebi> (<z:chebi fb="3" ids="16865">GABA</z:chebi>) is an inhibitory neurotransmitter and a ligand of <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor </plain></SENT>
<SENT sid="2" pm="."><plain>By inhibiting excitatory response, it may decrease complications associated with vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> and <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="17230">Hcy</z:chebi> specifically competes with the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptors and acts as an excitotoxic neurotransmitter </plain></SENT>
<SENT sid="4" pm="."><plain>Previously, we have shown that <z:chebi fb="0" ids="17230">Hcy</z:chebi> increases levels of <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase and reactive oxygen species (ROS), and decreases levels of <z:chebi fb="0" ids="15033">thioredoxin</z:chebi> and peroxiredoxin by antagonizing the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="17230">Hcy</z:chebi> treatment leads to activation of matrix metalloproteinases (MMPs) in cerebral circulation by inducing redox stress and ROS </plain></SENT>
<SENT sid="6" pm="."><plain>The hypothesis is that <z:chebi fb="0" ids="17230">Hcy</z:chebi> induces MMPs and suppresses tissue inhibitors of metalloproteinase (TIMPs), in part, by inhibiting the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor </plain></SENT>
<SENT sid="7" pm="."><plain>This leads to degradation of the matrix and disruption of the blood brain barrier </plain></SENT>
<SENT sid="8" pm="."><plain>The brain cortex of transgenic mouse model of HHcy (<z:chebi fb="0" ids="17755">cystathionine</z:chebi> β-synthase, CBS-/+) and <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor null mice treated with and without muscimol (<z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor <z:chebi fb="4" ids="48705">agonist</z:chebi>) was analysed </plain></SENT>
<SENT sid="9" pm="."><plain>The <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were measured by Q-RT-PCR </plain></SENT>
<SENT sid="10" pm="."><plain>Levels of MMP-2, -9, -13, and TIMP-1, -2, -3, and -4 were evaluated by in situ labeling and PCR-gene arrays </plain></SENT>
<SENT sid="11" pm="."><plain>Pial venular permeability to fluorescence-labeled albumin was assessed with intravital fluorescence microscopy </plain></SENT>
<SENT sid="12" pm="."><plain>We found that <z:chebi fb="0" ids="17230">Hcy</z:chebi> increases metalloproteinase activity and decreases TIMP-4 by antagonizing the <z:chebi fb="3" ids="16865">GABA</z:chebi>-A receptor </plain></SENT>
<SENT sid="13" pm="."><plain>The results demonstrate a novel mechanism in which brain microvascular permeability changes during HHcy and vascular <z:hpo ids='HP_0000726'>dementias</z:hpo>, and have therapeutic ramifications for microvascular disease in Alzheimer's patients </plain></SENT>
</text></document>